Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
My thoughts exactly.
Also the trademark was registered in early November and wasn't picked up by the army of Avacta researchers. Yet the 1 guy who did find the MeduFlow info went onto to fake a brochure...…..very likely imo.
I attend 6 - 8 exhibitions every year and our marketing department are always ****ing up brochures etc. That brochure filled in some gaps for me following my discussions with Medusa19 and made sense of a few things. As many have written, pick up the phone or email them as I certainly found it enlightening.
Good morning, hope everyone is well.
A decent week for Avacta I thought, we got........
1. 15% share price increase
2. Mologic funding PHD's at Leeds UNI using Affimers for selected viruses listed on the World Health Organization. This work was covering diagnostics and therapeutics - neutralizing therapies.
3. More info about the amazing performance of AffiDX from the Medusa brochure - yes I 100% believe it to be genuine.
4. Point Biopharma presentation which now lists they have 2 programmes in development using Canseek (precision technology), we was only told about 1 previously. - that's confidence.
5. Fantastic presentation from Avacta regarding the enormous potential of their therapeutic platforms, good indication AVA600 is on track for me.
I personally have never been more confident in where Avacta is heading, very excited for the next few weeks.
GLA
Was about to post it, but seems you beat me to it @gmcc
Great presentation though and with AVA6000 now 14 weeks in, it’s a good indication everything is on track.
The potential for these platforms very ceases to amaze me.
Never been more confident in where Avacta is heading:)
That’s a great find.
This part got my attention……
This project will be delivered in partnership with Mologic. If a student is recruited, the project will be converted to an i-CASE (industry partnership) following the start date of October 2022.
https://www.linkedin.com/posts/medilinkuk-international_healthcare-medical-international-activity-6861990865779351552-eQpD
We’re looking forward to supporting 25 innovative medical technology and healthcare companies at MEDICA - Leading International Trade Fair this month, where they will be meeting with international buyers, visitors, suppliers and stakeholders and growing their businesses internationally.
It’s great to see so many companies excited about the prospect of getting back to a face-to-face international event.
Interested in learning more about who is exhibiting with us?
Visit their profiles for more information: Viamed Ltd Hunter Urology PRECISION PARTS UK LIMITED Speciality Fibres and Materials Ltd Fortuna Healthcare Chemence Limited AtlantaMed AIBODY Medusa19.com EziDrops Bluetree Medical C Major Medical Conductive Transfers Yourgene Health AG INSTRUMENTS LIMITED Advanced Healthcare Technology Ltd. Tytek Medical Inc. Brandon Medical - OT(OR), ICU equipment NPZ TECHNOLOGY LIMITED Physicool MedDX Solutions Limited Optimum Medical Globus Group Department for International Trade (DIT) Midlands Engine Northern Powerhouse
#healthcare #medical #international #medica2021 #exhibitions
I cant see anything but AffiDX being the main focus of Medusa 19's stand at Medica. They haven't promoted their questionable saliva antibody test in months now.
https://gsbs.tufts.edu/facultyResearch/faculty/bachovchin-william/research
Some data out of Tufts…..
https://www.terrapinn.com/conference/festival-of-biologics/speaker-matthew-VINCENT.stm
Festival of Biologics Day 1 @ 17:30
FAP-Activated Prodrugs and Antibody-Drug Conjugates: TME Targeting of Innate Immune Activators
Matthew Vincent, VP of Business development & Therapeutic strategy, Avacta
https://www.medica-tradefair.com/vis/v1/en/exhibitors/medcom2021.2694929?oid=80396&lang=2&_query=Medusa19
So Medusa19 have a stand at the upcoming Medica show in Germany. Interestingly they are right opposite The Department for International Trade as well.
Slight change to to the page this morning, the following was added.....
Avacta Group plc is incorporated in the United Kingdom and its principal place of operation is the United Kingdom.
Not sure why they would feel the need to highlight that.....
https://avacta.com/interview-with-fiona-mclaughlin-avacta-chief-scientific-officer-therapeutics/
What attracted you to Avacta?
Avacta is entering an exciting stage as a clinical development organisation, and I could see the potential to really shape the pipeline of its therapeutics division as the company enters a new phase.
For the last few years, I had been working as a consultant, which gave me a fantastic network and the flexibility to work with several organisations, from biotech to venture capitalists, and not-for-profit organisations such as Cancer Research UK. After 25 years in drug development, I was keen to move to an oncology-focused biopharmaceutical company where I could use my expertise to drive progress in the field and bring new, innovative drugs to the market.
At Avacta I’m now part of a team that is committed to developing clinically differentiated cancer therapies with the potential to improve dosing regimens, efficacy, and outcomes for patients.
What do you hope to achieve in the CSO role?
My role is to identify and prioritise assets in Avacta’s therapeutic portfolio to drive them towards the clinic. We have built up the translational science team, ensuring we are able to design the most effective clinical studies, as well as expand the pipeline using our pre|CISION™ and Affimer® platform technologies, and increase our interactions with world-class academic labs and industries, to deliver first-in-class therapeutics.
In 2018 my identical twin sister was diagnosed with breast cancer, still in her forties—I have known many people affected by cancer, but no one this close. She was diagnosed with a type of tumour for which there was an existing antibody therapy, though the best result in trials came from the antibody being delivered in combination with chemotherapy. She underwent months of chemotherapy, antibody treatment, surgery, and radiotherapy, and, having witnessed first-hand the side-effects of combined chemotherapeutic drugs, I appreciate now more than ever the need to develop treatments that are better tolerated by patients. Anthracycline was one of the drugs she was given, and I am now working on developing a better tolerated version at Avacta.
The pre|CISION™ and Affimer® platforms are both very exciting, offering the potential to advance treatment options for patients. I hope to continue to work with the team to bring novel, effective cancer therapies to market, particularly addressing areas of high unmet clinical need, such as pancreatic cancer.
Do you have any advice for someone starting a career in research science?
Don’t give up! Early-stage drug development is a long and complex process that comes with many challenges—you need to be able to problem solve constantly, but the experience is invaluable. The more experience you gain, the more you can draw on that to successfully address the problem in hand.
Find out more about careers at Avacta.
The point I would highlight is Avacta is perfectly placed to tackle cancer head on from all angles including diagnostics.
This what Fiona McLaughlin said in the recent Bioscience Today article….
“This is why everything that we do in the lab has to be tangible. We are making drugs to deliver to patients, or developing companion diagnostics to help deliver a precision medicine approach to cancer treatment”
https://www.linkedin.com/posts/streambiosciences_discoverbright-activity-6859404722495905792-yHsd
Our exceptionally bright CPNs, conjugated with an anti-carcinoembryonic antigen (CEA) affimer, could enhance bowel cancer treatment and diagnostics.
This is being studied as part of our BBSRC-funded collaboration with The University of Manchester and the University of Leeds.
Learn more in the case study here: https://lnkd.in/eEsqphA #DiscoverBright
BioServUK (a Calibre Scientific, Inc. company) continues its successful partnership with Avacta Life Science in distributing their high-performance AffiDX® SARS-CoV-2 Lateral Flow Test which is developed and manufactured in the UK, based on their proprietary Affimer® technology.
Top Features of the Lateral Flow Test:
- 98% sensitivity
- 99% specificity
- CE IVD marked
- MHRA registered
- Patient-friendly: Anterior nares (nasal) swabs samples for a more comfortable collection
- Monitored against emerging Variants: Proven to detect the new Delta variant (B.1.617.2) as per a recent study
- Rapid & Simple: Easy to use, simple work-flow, results in only 20 minutes
Ordering Information:
Product code: BSV-COV-11711125
Product name: AffiDX® SARS-CoV-2 Antigen Lateral Flow Test
Pack size: 1 Pack (25 Tests)
https://lnkd.in/g9YfCrk
info@BioServUK.com
+44 (0)114 224 2235
#bioservuk #avacta #calibrescientific #covid19testing #covid19pandemic #covid19awareness #covid19response #sarscov2 #covid #covid19news #lifesciences #biotechnology #viruses #lateralflowtest #covidtesting #pandemic #pcrtest
https://www.linkedin.com/posts/bioservuk_bioservuk-avacta-calibrescientific-activity-6858723046883237889-vcHo
https://www.kevinhollinrake.org.uk/news/visiting-global-test-manufacturer-sand-hutton
Last week, I visited the York headquarters of Abingdon Health: A Northern Powerhouse, global manufacturer of lateral flow device tests. I met with Chris Hand (Chairman), Chris Yates (CEO) and Melanie Ross (CFO) to discuss the role Abingdon Health played during the outbreak of the pandemic. In response to the Government’s request to develop a COVID-19 antibody rapid lateral flow test that screens for an immune response following COVID-19 infection or vaccination, Abingdon Health have transformed their business over the last 18 months.
It was fascinating to see such innovation and growth happening right here in Sand Hutton, now expanding across Yorkshire. As well as growing from 50 people to almost 200 people, Abingdon Health have also built an additional 9 laboratories across their York and Doncaster sites and invested in cutting edge lateral flow test automation technology. Growing companies such as this is vital to our economy, not least for providing job opportunities across Yorkshire and the UK.
Along with the Chief Operations Officer, Olly Gardner, and Operations Director, Dave Goldsworthy, I toured the Sand Hutton state-of-the-art manufacturing facility to gain an understanding of new automated assembly equipment - vital for producing high-quality lateral flow products at large volumes. As well as seeing the manufacture of Abingdon Health’s ‘AbC’ COVID-19 antibody lateral flow test, I also saw several of the other lateral flow tests being manufactured at the Abingdon Health York site, including a COVID-19 antigen test that and also an equine, animal health lateral flow test.
"I also saw several of the other lateral flow tests being manufactured at the Abingdon Health York site, including a COVID-19 antigen test"
Looks like AffiDX is rolling of the Ginoli machines at Abingdon Health:)
Can't help thinking that Avacta have a relationship with Katalyst Laboratories. Rob Ford always liking their posts on LinkedIn and commenting on their new testing centre at Heathrow.
https://www.linkedin.com/posts/markfwalker_covid19travel-heathrowairport-covid-activity-6855446153593450496-bvtr/